Determinants and clinical significance of plasma oxidized LDLs in older individuals. A 9 years follow-up study

Atherosclerosis

Volumn 226, Issue 1, 2013, Pages 201-207

  Zuliani, Giovanni ^a   Morieri, Mario Luca ^a   Volpato, Stefano ^a   Vigna, Giovanni B ^a   Tch, Cristina Bosi ^a   Maggio, Marcello ^b   Cherubini, Antonio ^c,g   Bandinelli, Stefania ^d,e   Guralnik, Jack M ^f   Ferrucci, Luigi ^f  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d ASF Geriatric Rehabilitation   (Italy)

^e Tuscany Regional Health Agency   (Italy)

^f NATIONAL INSTITUTE ON AGING   (United States)

^g INRCA   (Italy)

Author keywords

Aging; Cardiovascular disease; Mortality; Oxidized LDL

Indexed keywords

BETA CAROTENE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; OXIDATION; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE PRICING;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEINS, LDL; MALE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 84871386021     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.10.028     Document Type: Article

References (37)

1. Steinberg D., Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation 1997, 95:1062-1071.
2. Salonen J.T., Yla-Herttuala S., Yamamoto R., et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992, 339:883-887.
3. Toshima S., Hasegawa A., Kurabayashi M., et al. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 2000, 20:2243-2247.
4. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320:915-924.
5. Meisinger C., Baumert J., Khuseyinova N., Loewel H., Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 2005, 112:651-657.
6. Scheffer P.G., Bos G., Volwater H.G., Dekker J.M., Heine R.J., Teerlink T. Associations of LDL size with in vitro oxidizability and plasma levels of in vivo oxidized LDL in type 2 diabetic patients. Diabet Med 2003, 20:563-567.
7. Nakhjavani M., Khalilzadeh O., Khajeali L., et al. Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol. Lipids 2010, 45:321-327.
8. van der Zwan L.P., Teerlink T., Dekker J.M., et al. Circulating oxidized LDL: determinants and association with brachial flow-mediated dilation. J Lipid Res 2009, 50:342-349.
9. Njajou O.T., Kanaya A.M., Holvoet P., et al. Association between oxidized LDL, obesity and type 2 diabetes in a population-based cohort, the Health, Aging and Body Composition Study. Diabetes Metab Res Rev 2009, 25:733-739.
10. van Tits L.J., van Himbergen T.M., Lemmers H.L., de G.J., Stalenhoef A.F. Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2006, 185:307-312.
11. Holvoet P., Kritchevsky S.B., Tracy R.P., et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 2004, 53:1068-1073.
12. Shimada K., Mokuno H., Matsunaga E., et al. Predictive value of circulating oxidized LDL for cardiac events in type 2 diabetic patients with coronary artery disease. Diabetes Care 2004, 27:843-844.
13. Shimada K., Mokuno H., Matsunaga E., et al. Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis 2004, 174:343-347.
14. Johnston N., Jernberg T., Lagerqvist B., Siegbahn A., Wallentin L. Oxidized low-density lipoprotein as a predictor of outcome in patients with unstable coronary artery disease. Int J Cardiol 2006, 113:167-173.
15. Tsutsui T., Tsutamoto T., Wada A., et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol 2002, 39:957-962.
16. Charach G., George J., Afek A., et al. Antibodies to oxidized LDL as predictors of morbidity and mortality in patients with chronic heart failure. J Card Fail 2009, 15:770-774.
17. Ferrucci L., Bandinelli S., Benvenuti E., et al. Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. J Am Geriatr Soc 2000, 48:1618-1625.
18. Maruyama C., Imamura K., Teramoto T. Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia. J Atheroscler Thromb 2003, 10:186-191.
19. Boizel R., Benhamou P.Y., Lardy B., Laporte F., Foulon T., Halimi S. Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. Diabetes Care 2000, 23:1679-1685.
20. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
21. Levey A.S., Stevens L.A., Schmid C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.
22. Zuliani G., Galvani M., Maggio M., et al. Plasma soluble gp130 levels are increased in older subjects with metabolic syndrome. The role of insulin resistance. Atherosclerosis 2010, 213:319-324.
23. Martin A., Zulueta J., Hassoun P., Blumberg J.B., Meydani M. Effect of vitamin E on hydrogen peroxide production by human vascular endothelial cells after hypoxia/reoxygenation. Free Radic Biol Med 1996, 20:99-105.
24. van L.M., Harries A.D., Kumwenda J.J., et al. Micronutrient malnutrition and wasting in adults with pulmonary tuberculosis with and without HIV co-infection in Malawi. BMC Infect Dis 2004, 4:61.
25. Lauretani F., Semba R.D., Bandinelli S., et al. Low plasma selenium concentrations and mortality among older community-dwelling adults: the InCHIANTI study. Aging Clin Exp Res 2008, 20:153-158.
26. Pisani P., Faggiano F., Krogh V., Palli D., Vineis P., Berrino F. Relative validity and reproducibility of a food frequency dietary questionnaire for use in the Italian EPIC centres. Int J Epidemiol 1997, 26(Suppl. 1):S152-S160.
27. Nordin F.G., Hedblad B., Berglund G., Nilsson J. Plasma oxidized LDL: a predictor for acute myocardial infarction?. J Intern Med 2003, 253:425-429.
28. Austin M.A., King M.C., Vranizan K.M., Krauss R.M. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990, 82:495-506.
29. Kondo A., Muranaka Y., Ohta I., et al. Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL. Clin Chem 2001, 47:893-900.
30. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. Antiinflammatory properties of HDL. Circ Res 2004, 95:764-772.
31. Vasankari T., Ahotupa M., Toikka J., et al. Oxidized LDL and thickness of carotid intima-media are associated with coronary atherosclerosis in middle-aged men: lower levels of oxidized LDL with statin therapy. Atherosclerosis 2001, 155:403-412.
32. Stephens J.W., Gable D.R., Hurel S.J., Miller G.J., Cooper J.A., Humphries S.E. Increased plasma markers of oxidative stress are associated with coronary heart disease in males with diabetes mellitus and with 10-year risk in a prospective sample of males. Clin Chem 2006, 52:446-452.
33. Jialal I., Norkus E.P., Cristol L., Grundy S.M. beta-Carotene inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1991, 1086:134-138.
34. Karppi J., Nurmi T., Kurl S., Rissanen T.H., Nyyssonen K. Lycopene, lutein and beta-carotene as determinants of LDL conjugated dienes in serum. Atherosclerosis 2010, 209:565-572.
35. Kontush A., Weber W., Beisiegel U. Alpha- and beta-carotenes in low density lipoprotein are the preferred target for nitric oxide-induced oxidation. Atherosclerosis 2000, 148:87-93.
36. Jialal I., Grundy S.M. Effect of combined supplementation with alpha-tocopherol, ascorbate, and beta carotene on low-density lipoprotein oxidation. Circulation 1993, 88:2780-2786.
37. Gordon D.J., Rifkind B.M. Treating high blood cholesterol in the older patient. Am J Cardiol 1989, 63:48H-52H.